Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
6,151 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06076226 | A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation | recruiting | — | 2,500 | Zhejiang UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06070740 | First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma | recruiting | Phase 2 | 22 | Peking Union Medical College HospitalOTHER | 1 |
| Oct 6, 2023 |
| clinicaltrials |
| NCT06062927 | Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma | recruiting | — | 60 | Peking Union Medical College HospitalOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT06060769 | Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging | recruiting | — | 1,200 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04631770 | Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC | recruiting | N/A | 1,362 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06035250 | AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy | recruiting | — | 200 | Chinese Academy of SciencesOTHER_GOV | 2 | Sep 28, 2023 | clinicaltrials |
| NCT06055738 | Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC | recruiting | Phase 2 | 20 | Tang-Du HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06055816 | Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 40 | Zhejiang Cancer HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06056115 | Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic | recruiting | N/A | 20 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06056336 | Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 73 | Guo XufengOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06059521 | Software Refraction With Mobilerone Versus Retinoscopy(SRMR) | recruiting | N/A | 120 | Beijing Airdoc Technology Co., Ltd.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06059560 | Nutritional Intervention for Patients With Multiple Cancer Types | recruiting | N/A | 1,000 | First Hospital of China Medical UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05450029 | Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer(SILAR) | recruiting | Phase 2 | 51 | Yanhong DengOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03734952 | Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy | recruiting | N/A | 537 | Fujian Medical University Union HospitalOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT06041776 | Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations | recruiting | Phase 3 | 570 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04837625 | Study of Myasthenic Crisis in China | recruiting | — | 300 | Huashan HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05768529 | Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05992597 | ZR2 Sequential Immunochemotherapy for Newly Treated MCL | recruiting | Phase 2 | 48 | Zhejiang Cancer HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06042998 | A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer(CLASS14) | recruiting | N/A | 588 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043973 | Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance | recruiting | Phase 3 | 98 | Qianfoshan HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043999 | Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients | recruiting | N/A | 392 | Sun Yat-sen UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06045091 | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06039631 | Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer | recruiting | Phase 2 | 82 | Fudan UniversityOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05994859 | SIRT for Potentially Resectable HCC | recruiting | N/A | 35 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT04728724 | Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer | recruiting | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06035016 | Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer | recruiting | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05511623 | Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer | recruiting | Phase 2 | 112 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06019702 | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms | recruiting | Phase 1 | 20 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06026774 | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms | recruiting | Phase 1 | 20 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06026800 | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms | recruiting | Phase 1 | 20 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06031246 | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) | recruiting | Phase 3 | 634 | Fudan UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06002425 | Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models | recruiting | N/A | 400 | Chinese Academy of SciencesOTHER_GOV | 4 | Sep 8, 2023 | clinicaltrials |
| NCT05980702 | 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC(HNC-SYSU-002) | recruiting | Phase 2 | 192 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT06026878 | GNT Induction Treatment in Locally Advanced NPC | recruiting | Phase 3 | 228 | Air Force Military Medical University, ChinaOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | recruiting | Phase 3 | 140 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04743479 | Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)(ESPRIT-AI) | recruiting | — | 5,000 | Changhai HospitalOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05468970 | Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors | recruiting | — | 6,000 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05378087 | Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer | recruiting | N/A | 1,956 | Chongqing University Cancer HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05962502 | Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy | recruiting | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05047510 | GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma | recruiting | N/A | 60 | Chinese Academy of SciencesOTHER_GOV | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05336539 | A Community Population Screening Cohort Study Based on Polygene Methylation Detection for Colorectal Cancer in Yangzhou | recruiting | — | 80,000 | Singlera Genomics Inc.INDUSTRY | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05956847 | The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric | recruiting | — | 1,000 | Xijing HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06015802 | Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors | recruiting | — | 300 | Sun Yat-sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05631886 | Combination of CAR-DC Vaccine and ICIs in Malignant Tumors | recruiting | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05871762 | Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer(COMREC) | recruiting | — | 3,705 | Peking Union Medical College HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT06011694 | The Jinling Cohort | recruiting | — | 15,000 | Nanjing Shihejiyin Technology, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05879783 | Optical Biopsy for Peritoneal Nodules in Colorectal Patients | recruiting | N/A | 278 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT06006650 | Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell | recruiting | Phase 2 | 114 | Tang-Du HospitalOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05617859 | Lenvatinib for Advanced Bone and Soft Tissue Sarcoma | recruiting | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials